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To report (using linked laboratory data) the incidence, prevalence and geographic variation of chronic
kidney disease (CKD) across the whole island population of Tasmania, Australia.
Methods
A retrospective cohort study (the Tasmanian Chronic Kidney Disease study (CKD.TASlink)) using
linked data from five health and two pathology datasets from the island state of Tasmania, Australia
between 1/1/2004 and 31/12/2017. We used data on 460,737 Tasmanian adults (aged 18 years and
older, representing 86.8% of the state’s population) who had a serum creatinine measured during
the study period. We defined CKD as per Kidney Disease Outcomes Quality Initiative, requiring
two measures of estimated glomerular filtration rate (eGFR) <60mL/min/1.73m2, at least three
months apart. Kidney replacement therapy (KRT) included dialysis or kidney transplantation.
Results
We identified 56,438 Tasmanians with CKD during the study period, equating to an age-standardised
annual incidence of 1.0% and a prevalence of 6.5%. These figures were higher in women,
older Tasmanians and people living in the North-West region of Tasmania. Testing for urinary
albumin:creatinine ratio is increasing, with 28.5% of women and 30.8% of men with stage 3 CKD
having both an eGFR and uACR in 2017. Use of KRT was consistently seen in >65% of Tasmanians
with eGFR <15mL/min/1.73m2.
Conclusion
There is geographic and gender variation in the incidence and prevalence of CKD, but it is reassuring
to see that the majority of people with end-stage kidney failure are actually receiving treatment with
dialysis or transplantation.
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Background
The burden of chronic kidney disease (CKD) in Australia
is increasing rapidly [1]. However, the financial cost of
treating all people with kidney failure with dialysis or
kidney transplantation is unsustainable and the community
cost undesirable [2]. Early detection and intervention to
prevent progression of CKD is relatively simple, cheap and a
community priority. The population of Tasmania, an island
state of Australia, has a high burden of chronic disease,
including hypertension, obesity, cardiovascular disease and
mental health problems [3]. All of these are known risk factors
for the development of kidney disease, a progressive condition
that once it is well established, it is (currently) not possible to
reverse.
Kidney disease is diagnosed by measuring albumin in
a urine sample (urine albumin:creatinine ratio, uACR) and
creatinine in a blood test. The latter is then used to
estimate glomerular filtration rate (eGFR), a measure of kidney
function. CKD is defined as an abnormality of structure or
function, present for ≥3 months, and is classified based on
cause, eGFR and uACR categories. These categories allow
standardised staging of CKD from stage one (normal, eGFR
≥90 mL/min/1.73m2) through stages two (mild decreased,
eGFR 60–89mL/min/1.73 m2), three (moderate decrease,
eGFR 30–59mL/min/1.73 m2), four (severe decreased, eGFR
15–29 mL/min/1.73m2) and stage five (kidney failure, eGFR
≤15 mL/min/1.73m2). Use of kidney replacement therapy
(dialysis or kidney transplantation) occurs in stage five when
appropriate.
Population estimates of CKD in Australia come from
the Australian Health Survey (2011–12), where approximately
11,000 Australians each provided a single blood and urine
sample. This population survey reported a higher prevalence
of CKD per population in Tasmania than in any other
state [3]. Albuminuria was present in 8.5% of Tasmanians
compared with 7.7% in the rest of Australia, whilst
eGFR ≤60 mL/min/1.73m2 occurred in 4.6% of Tasmanians
compared with 3.5% in the rest of Australia [3]. Therefore,
by standard definitions [4], Tasmania has the highest state
prevalence of CKD in Australia.
Despite the increased prevalence of CKD, Tasmania has
the lowest incidence of kidney failure treated with dialysis
or transplantation (Kidney Replacement Therapy, KRT) of
any Australian state or territory. In 2018 the incident rate of
KRT was 87 per million population (pmp) in Tasmania, but
124pmp for Australia overall [5]. The prevalence rate of KRT
was 939pmp, lower than national rate of 1026pmp, with the
largest difference being use of dialysis where the prevalence
was 400pmp in Tasmania compared to 536pmp in Australia
overall [5]. Clearly there is a gap between the high rate of CKD
reported by the Australian Health Survey and the low use of
KRT. We first identified this gap in Tasmania in 2009 [6] and
it was demonstrated again in 2011 by the Australian Institute
of Health and Welfare report on total incidence of end-stage
kidney disease. This report showed that for all people who die
with kidney failure, Tasmanians were less likely to be treated
with KRT than other Australians [7].
Tasmania is a small island state of approximately
68,000 km2 located 250km to the south of mainland Australia.
KRT facilities in Tasmania are currently provided in the
North-West (Burnie), North (Launceston General Hospital
and Kings Meadows) and South (Royal Hobart Hospital and
Newtown), corresponding to resident adult (age 18 years
and older) populations of approximately 87,000, 113,000
and 209,000 respectively [8]. All of Tasmania is classified
as regional, remote or very remote according to Australian
Standard Geographical Classification with distances between
place of residence and dialysis facility up to 200km [9]. All
acute transplant surgery takes place in Melbourne, Victoria.
To understand the relationship between kidney health and
disease in the community and access to KRT in specific
locations across the island state, we established a linked
dataset containing both community and hospital data [10].
The aim of this present study was to confirm the state
incidence and prevalence of CKD and use of KRT in Tasmania.
Methods
The Tasmanian Chronic Kidney Disease study (CKD.TASlink)
was a retrospective cohort study that examined a dataset
created by linkage of seven existing local health information
datasets. Detailed methods and linked data obtained are
available elsewhere [10]. Briefly, pathology data on 490,012
individuals (from birth) was obtained from community and
hospital-based pathology providers between 1/1/2004 to
31/12/2017. Individuals were selected if they had a serum
creatinine requested by their treating doctor. Linkage to the
Australia and New Zealand Dialysis and Transplant Registry
(ANZDATA), Tasmanian public hospital admitted patient
dataset, Tasmanian public hospital emergency presentation
dataset, Tasmanian cancer registry and the Tasmanian death
registry was performed by the Tasmanian Data Linkage
Unit. These linked datasets were specifically chosen to allow
us to identify and follow longitudinally an individual with
CKD (via the pathology dataset), examine their health
service use (emergency presentations and admitted patient
datasets), development of additional comorbidities (admitted
patient dataset and cancer registry) and outcomes of
kidney replacement therapy (ANZDATA) or death (death
registry).
Representativeness of the dataset
The estimated Tasmanian resident population (ERP) in 2017
was 522,410 of which 409,729 were aged 18 years and older [8].
Individuals identified within the dataset comprised 47.6% of
the overall adult Tasmanian population when studied over one
year, 74.2% over three years and 86.8% over five years in the
period 2013 to 2017 [10]. As this is a pathology dataset based
on serum creatinine, annual representation varied with age: for
instance, in 2017, 82.5% of Tasmanian 80 to 84-year-olds were
represented, but only 7.8% of people under 18 years. Ethnicity
was recorded, but not considered in the analysis.
Data
Data is reported by count (actual number of individuals with
CKD), crude rate (number or percentage of people with CKD
per 10,000 estimated resident population (ERP) per calendar
year), age-specific rate (where numerator and denominator
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relate to the same age group) and age-standardised rate
(using direct age-standardisation method by comparing to the
Australian ERP) [8].
Geocoding of individual addresses was used to link to
the Geocoded National Address File (G-NAF), then allocated
to statistical area as per Australian Statistical Geography
Standard [9]. For this study we used statistical area 4 (SA4). In
Tasmania there are four SA4 areas: Hobart (2017 estimated [8]
total resident adult (age 18 years and older) population
178,887), South East (30,415), Launceston and North East
(113,231), West and North West (87,195). For the purposes
of this study we combined Hobart and South East, so that all
analyses are by the remaining 3 areas corresponding to major
hospitals/health services.
Diagnosis of CKD
Chronic kidney disease in individuals 18 years and older was
defined using Kidney Disease Improving Global Outcomes
(KDIGO) criteria [11] (with eGFRcreat calculated using the
2009 CKD Epidemiology Collaboration (CKD-EPI) creatinine
equation (CKD-EPIeGFR) [12]), This required two reports of
abnormal kidney function (eGFR <60 mL/min per 1.73 m2)
at least 3 months apart or, in those with eGFR ≥60 mL/min
per 1.73m2, a urinary albumin-creatinine ratio (uACR)
≥2.6 mg/mmol in males) or ≥3.5 mg/mmol in females. CKD
severity was classified according to the KDIGO CKD staging
system using both the eGFR and uACR measures. For
this, we considered stages G1–G5 for eGFR and A1–A3 for
uACR categories [11]. Tasmanian laboratories use enzymatic
assays for measurement of creatinine, immunoassay for urinary
albumin and all results are isotope dilution mass-spectrometry
(IDMS)-aligned as previously reported [13].
Definition of incidence
Within the study period, the first-time a patient met
the KDIGO CKD criteria within our pathology dataset or
had a start date in the ANZDATA dataset (indicating
commencement of KRT), they were defined as having CKD.
Definition of prevalence
If a patient had started in the ANZDATA dataset prior to
our study period, they were categorised as ‘prevalent’ CKD in
2004 (start of study period). A patient remained a prevalent
case until we had a confirmation of death from any of
our datasets (death, AP, cancer, ANZDATA). To minimise
bias, we censored observations at 18 months from last
eGFR measurement, if no further eGFR measurements were
made.
To enable comparisons with previous publications,
including the Australian Health Survey [3] and the Australian
Diabetes, Obesity and Lifestyle study (AUSDIAB) which
did not use the standard Kidney Disease Outcomes Quality
Initiative (KDOQI) definitions, we also considered a single-
test definition of CKD where eGFR <60 mL/min/1.73m2 or
uACR was recorded on the first test in any one calendar
year. A single test cannot exclude short-term variation, likely
due to intercurrent illness (rather than true chronic kidney
disease).
The CKD.TASlink protocol was reviewed and approved by
the Tasmanian Human Research Ethics Committee (Approved
study H0016499).
Results
During the 14-year study period, 460,737 Tasmanian adults
had a serum creatinine measured. The CKD Cohort was
detected as 56,438 which consisted of those detected by
pathology met the international definition of CKD (56,039)
or presence on the ANZDATA registry (399) [10]. There were
1051 individuals treated with KRT over the 14-year period,
many subsequent to diagnosis.
Incidence
The age-standardised annual incidence has plateaued over the
last decade to around 99 per 10,000 Tasmanians or 1% of the
adult population (Table 1).
Up to 6,264 Tasmanians developed CKD for the first time
each year during the study period. CKD was rarely seen in
the 18–54 year-old age group with an incidence of just 8 per
10,000 in 2017, but higher in the 55–74 year-old age group at
137 per 10,000, and up to 677 per 10,000 for those aged 75
years and older (Figure 1).
There are consistent geographic differences in the age-
standardised annual incidence of chronic kidney disease. In
2017, Launceston and North-East region had a 12% higher (98
per 10,000 age-standardised population) and West and North-
West region had a 45% higher incidence (128 per 10,000)
compared with Hobart and South-East (87 per 10,000)
Tasmania (Supplementary Table 1). Whilst there has been
an overall reduction in incidence during the study period,
incidence in the West and North-West region remains high.
Women were consistently more likely to develop CKD than
men (Supplementary Table 2). The age-standardised annual
incidence has reduced in the last 10 years to around 105 per
10,000 Tasmanian women or 91 per 10,000 Tasmanian men.
Prevalence
The overall prevalence of CKD in Tasmania (using two
measures of eGFR at least 90 days apart) increased nearly 50%
between 2007 to 2017, so in 2017 there were more than 33,000
Tasmanians with CKD. This age-standardised prevalence has
somewhat stabilised in the last 5 years at around 650 per
10,000 (6.5%), but is 31% higher in Tasmanian women than
Tasmanian men, with age-standardised prevalence of 734 per
10,000 women and 562 per 10,000 men (Figure 2).
Using a single-test definition of CKD to allow comparison
with the Australian Health Survey, AUSDIAB study and other
single-measure reports, annual prevalence was double that
of the two-measure KDOQI definition, consistently around
12–13% (Figure 3).
There are clear geographical differences (Supplementary
Table 3) in the age-standardised prevalence of CKD with the
West and North-West having 18% greater prevalence (724 per
10,000) compared to Hobart and South East Tasmania (616
per 10,000) in 2017. This gap has increased in the last 10
years; in 2008 the relative difference was only 11%.
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Table 1: Incidence of CKD in Tasmania by calendar year using KDOQI definitions [4]
Crude Age standardised
Year ERP (18+)* Number with CKD
% per 10,000 % per 10,000 95% CI
2004 365,315 5218 1.43 143 1.38 138 134.3–141.7
2005 363,771 6264 1.72 172 1.76 176 171.6–180.4
2006 361,388 5025 1.39 139 1.53 153 148.8–157.2
2007 361,190 4204 1.16 116 1.34 134 129.9–138.1
2008 363,186 3322 0.91 91 1.09 109 105.3–112.7
2009 366,960 2944 0.80 80 0.97 97 93.5–100.5
2010 370,616 3286 0.89 89 1.05 105 101.4–108.6
2011 372,643 3876 1.04 104 1.22 122 118.2–125.8
2012 371,975 4381 1.18 118 1.38 138 133.9–142.1
2013 370,730 4515 1.22 122 1.43 143 138.8–147.2
2014 370,478 3494 0.94 94 1.12 112 108.3–115.7
2015 371,571 3164 0.85 85 1.00 100 96.5–103.5
2016 373,213 3149 0.84 84 0.95 95 91.7–98.3
2017 376,941 3314 0.88 88 0.99 99 95.6–102.4
∗ERP (18+years) corrected for existing prevalence.
CKD: Chronic kidney disease, KDOQI: Kidney Disease Outcomes Quality Initiative [4], ERP: Estimated resident population, 18+:
aged 18 years and older. 95% CI: 95th percentile confidence intervals.
Figure 1: Incidence of CKD in Tasmania according to different age groups
Whilst the increase in the number of Tasmanians with CKD
was predominantly seen in the earlier stages G1-G3a, the latter
stages (G3b, G4 and G5) show a 39% increase over the last
decade from 6,871 in 2007 to 9,560 in 2017 (Figure 4 and
Supplementary Table 4).
This data also confirms that among Tasmanians with end-
stage kidney failure (eGFR <15 mL/min/1.73m2), 60–70%
are treated with KRT in any one year; this has remained
consistent over the last 10 years (Supplementary Table 4).
Testing for urinary albumin remains low, with just 28.5%
of women and 30.8% of men with stage 3 CKD having both
an eGFR and uACR in 2017 (Table 2 and Figure 5). Testing
is more likely if resident in the North or North West, as well
as for people with comorbid diabetes.
Discussion
Here we report the most comprehensive study of CKD
conducted in any Australian state. Taking a whole of
population approach, we report the incidence and prevalence
of CKD in Tasmania over a 14-year period using community
and hospital pathology data. We confirm the slow, steady
growth of CKD, predominantly in stages 3a and 3b, but with
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Figure 2: Prevalence of (age-standardised) prevalence of CKD by gender
Figure 3: Prevalence of eGFR <60 mL/min/1.73m2 in Tasmania using a single measure (first test) in a calendar year
variation by age, gender and geography. Annual incidence
is approximately 1.0%, with prevalence at 6.5% using
international definitions [11].
The prevalence of CKD in Australia (using a single
measure of eGFR) has been previously ascertained [3, 14, 15].
In a 2010 study, White and colleagues tested creatinine
once in 11,247 people aged 25 years and over for the
AUSDIAB study during 1999–2000 and identified 5.8% had
an eGFR <60 mL/min/1.73m2 [15]. The Australian Health
Survey measured creatinine once in 2011–2012 and reported a
prevalence of eGFR <60 mL/min/1.73m2 in 3.6% of 17,042
Australian aged 18 years and over [3]. Using data from
Australian general practices, we have previously reported a
national prevalence of 5.1% using a single measurement of
creatinine, and 4.1% when using KDIGO criteria [14]. The
more stringent KDOQI two-measurement prevalence of 6.5%
and the single-measurement prevalence of 12% confirms the
relatively high community burden of CKD in Tasmania.
The increase in prevalence over the 14-year study period
is also of interest, with a greater than 50% increase overall
and 40% increase in the prevalence of stages G3b, G4 or
G5. No previous study has provided this 14-year longitudinal
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Figure 4: Prevalence per year by CKD Stage
view of CKD in Australia as the Australian Health Survey
biomedical measures taken in 2011 have not been repeated.
Our previous work has reported this increase in early CKD [14],
but the increasing prevalence in latter stages of CKD is a
concern. Once the eGFR drops below 45 mL/min/1.73m2
(stage G3b, G4 or G5), morbidity and mortality (especially
cardiovascular) increase [16]. These findings highlight the need
for early detection and intervention to delay progression to
latter stages, with measures that fall well within the domain
of general practice (primary) care.
Testing for urinary albumin with a formal uACR through a
laboratory remains suboptimal yet is consistent with practice
across Australia [17]. Khanam et al., using the Medicine
Insight dataset from Australian general Practices reported
19.7% of Australians with stage G3 CKD had a uACR
tested in an 18-month period, but this increased to 68.7%
if diabetic [17]. It is possible that a dipstick urinalysis is being
used for testing for albuminuria or proteinuria, instead of the
recommended uACR.
In contrast to previously published data, the majority of
people in our study who reached stage 5 CKD in were treated
with dialysis or kidney transplants [6, 7]. The Australian
Institute of Health and Welfare (AIHW) had reported that
61.3% of Tasmanians who die with CKD are never treated
with dialysis or a transplant (increasing to 82% if aged
>70years) [7]. This is significantly higher than national figures
of 50% and 70% respectively from their study [7]. Our data
suggests that only 30–40% of Tasmanians with an eGFR
<15 mL/min/1.73m2 are not receiving KRT. The difference
may be in the methodology used. For our work we censured
people 12 months prior to death, whereas AIHW used coding
from death certificates, so it is possible a number of people
Table 2: Percentage of Tasmanians having both Urine-ACR and eGFR tested in a single year (2017)
Overall Hobart and Launceston and West and <75 <75 <75 <75
South East North East North West years years+DM years+HT years+DM+HT
eGFR >60mL/min/1.73m2 (Stage 1 & 2 CKD)
People 14.94 12.03 21.34 14.69 14.22 59.03 28.12 55.22
Women 12.94 10.33 18.20 13.25 12.10 58.05 26.93 55.82
Men 17.33 14.07 25.09 16.43 16.74 59.78 29.00 54.79
eGFR 30–60 mL/min/1.73 m2 (Stage 3 CKD)
People 29.59 24.57 36.50 30.74 35.92 61.96 40.44 56.58
Women 28.50 23.16 35.01 30.57 34.92 61.43 38.08 55.03
Men 30.80 26.14 38.20 30.93 36.93 62.39 42.32 57.73
Urine-ACR: Urine Albumin:Creatinine Ratio, eGFR: estimated Glomerular filtration rate. DM: Diabetes Mellitus, HT: Hypertension.
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Figure 5: KDOQI prevalence [11] of CKD in Women and Men using first eGFR and uACR measurement in the 2017
CKD: Chronic kidney disease, KDOQI: Kidney Disease Outcomes Quality Initiative [4], Urine-ACR: Urine Albumin:Creatinine Ratio,
eGFR: estimated Glomerular filtration rate, KRT: Kidney replacement Therapy (dialysis or transplantation).
have a decline in function in that last 12 months prior to
death.
The striking geographic differences in incidence and
prevalence is consistent with previous data on chronic disease
in regional and remote Australia. Whilst the whole of Tasmania
is classified as regional or remote, parts of the North West
region of Tasmania are classified as remote or very remote by
the Australian Statistical Geography Standard [9]. Compared
with major cities, rural Australians are treated with dialysis or
transplants less frequently (with incidence rate ratios of 0.85
for inner regional and 0.81 for outer regional) and have a higher
mortality rate (HR 1.08 for inner regional and 1.19 for outer
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regional) [18]. Australians living in ‘rural and remote’ areas
consistently report a greater number of health risk factors,
lower levels of education and income, less access to health
services and subsequently poorer health outcomes [19]. These
differences are seen in Tasmania, with the people resident in
the West and North-West of Tasmania having the highest
number of risk factors for chronic disease [20, 21], the highest
incidence and prevalence of CKD as well as the greatest growth
in CKD prevalence over the last decade.
A gender difference in CKD incidence and prevalence is well
known [22] and identified in our results. Tasmanian women had
up to 15% higher incidence and 30% higher prevalence of CKD
than Tasmanian men. These differences were consistent over
time and by geographic region. What we have not yet defined
is the progression of CKD in an individual (and whether men
progress faster) to an outcome of KRT or death. Both of these
factors will be vital to understand the natural history of CKD
in the Tasmanian community as men currently make up >60%
of all Tasmanians on KRT [5].
The strengths of this study include the whole of population
approach, the longitudinal 14-year study-period and the use
of both community and hospital-based laboratory data for
diagnosis of CKD. There are limitations however, many of
which are due to the retrospective, linked-data approach.
The datasets used primarily exist for other purposes and
therefore do not have the granular detail that a kidney-specific
dataset might have. Whilst we did include the major laboratory
providers, some smaller providers were not included, so it is
possible that a small number of Tasmanians are not included.
Conclusion
This study confirms the high and increasing community
prevalence of CKD, especially in stage 3 CKD in the state
of Tasmania. There are significant geographic and gender
variations, especially when it comes to use of KRT, but it
is reassuring to see that the majority of people with end-
stage kidney failure are actually receiving KRT, contrary to
previous Tasmanian reports. Understanding these geographic
and gender variations are important to deliver equitable access
to health services for the entire population of this island state
of Australia.
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Supplementary table 1: Incidence of chronic kidney disease in Tasmania by geographical region
Hobart and South East Launceston and North East West and North West
Crude Age standardised Crude Age standardised Crude Age standardised
No. No. No.
Year ERP with per % per 95% ERP with per % per 95% ERP with per % per 95%
(18+)* CKD 10,000 10,000 CI (18+)* CKD 10,000 10,000 CI (18+)* CKD 10,000 10,000 CI
2004 179620 2827 157 1.52 152 146.4–157.6 103963 991 95 0.93 93 87.2–98.8 81732 1400 171 1.62 162 153.5–170.5
2005 178979 3303 185 1.93 193 186.4–199.6 104029 1262 121 1.23 123 116.2–129.8 80762 1699 210 2.1 210 200–220
2006 177962 2418 136 1.54 154 147.9–160.1 103448 1305 126 1.35 135 127.7–142.3 79978 1302 163 1.76 176 166.4–185.6
2007 178032 1870 105 1.24 124 118.4–129.6 103377 1348 130 1.46 146 138.2–153.8 79781 986 124 1.41 141 132.2–149.8
2008 179719 1610 90 1.09 109 103.7–114.3 103218 1001 97 1.12 112 105.1–118.9 80248 711 89 1.04 104 96.4–111.6
2009 182099 1542 85 1.04 104 98.8–109.2 103733 797 77 0.91 91 84.7–97.3 81128 605 75 0.88 88 81–95
2010 184469 1649 89 1.09 109 103.7–114.3 104441 919 88 1.03 103 96.3–109.7 81706 718 88 1 100 92.7–107.3
2011 185964 1910 103 1.25 125 119.4–130.6 104864 1094 104 1.2 120 112.9–127.1 81815 872 107 1.21 121 113–129
2012 186477 2305 124 1.49 149 142.9–155.1 104293 1089 104 1.22 122 114.8–129.2 81206 987 122 1.35 135 126.6–143.4
2013 186511 2417 130 1.56 156 149.8–162.2 103783 1141 110 1.27 127 119.6–134.4 80435 957 119 1.34 134 125.5–142.5
2014 187200 1548 83 1.02 102 96.9–107.1 103419 1055 102 1.16 116 109–123 79858 891 112 1.29 129 120.5–137.5
2015 188849 1404 74 0.89 89 84.3–93.7 103293 892 86 0.99 99 92.5–105.5 79428 868 109 1.25 125 116.7–133.3
2016 190771 1338 70 0.82 82 77.6–86.4 103424 835 81 0.91 91 84.8–97.2 79017 976 124 1.32 132 123.7–140.3
2017 193635 1487 77 0.87 87 82.6–91.4 104259 914 88 0.98 98 91.6–104.4 79046 913 116 1.28 128 119.7–136.3
CKD: Chronic kidney disease, ERP: Estimated resident population, 18+: aged 18 years and older.
Supplementary table 2: Incidence of chronic kidney disease in Tasmania by gender
Women Men
Crude Age standardised Crude Age standardised
Number Number
Year ERP with % per % per 95% ERP with % per % per 95%
(18+)* CKD 10,000 10,000 CI (18+)* CKD 10,000 10,000 CI
2004 187674 2911 1.55 155 1.51 151 145.5–156.5 177641 2307 1.3 130 1.24 124 118.9–129.1
2005 186612 3662 1.96 196 2.03 203 196.4–209.6 177159 2602 1.47 147 1.49 149 143.3–154.7
2006 184995 2881 1.56 156 1.74 174 167.6–180.4 176393 2144 1.22 122 1.32 132 126.4–137.6
2007 184129 2369 1.29 129 1.51 151 144.9–157.1 177061 1835 1.04 104 1.16 116 110.7–121.3
2008 184478 1823 0.99 99 1.22 122 116.4–127.6 178708 1499 0.84 84 0.95 95 90.2–99.8
2009 185822 1551 0.83 83 1.05 105 99.8–110.2 181139 1393 0.77 77 0.87 87 82.4–91.6
2010 187228 1774 0.95 95 1.17 117 111.6–122.4 183388 1512 0.82 82 0.92 92 87.4–96.6
2011 187836 2049 1.09 109 1.35 135 129.2–140.8 184807 1827 0.99 99 1.09 109 104–114
2012 187552 2275 1.21 121 1.5 150 143.8–156.2 184423 2106 1.14 114 1.24 124 118.7–129.3
2013 187134 2373 1.27 127 1.58 158 151.6–164.4 183596 2142 1.17 117 1.26 126 120.7–131.3
2014 187302 1767 0.94 94 1.19 119 113.5–124.5 183176 1727 0.94 94 1.03 103 98.1–107.9
2015 188248 1617 0.86 86 1.06 106 100.8–111.2 183323 1547 0.84 84 0.91 91 86.5–95.5
2016 189496 1580 0.83 83 1.01 101 96–106 183717 1569 0.85 85 0.88 88 83.6–92.4
2017 191509 1663 0.87 87 1.05 105 100–110 185432 1651 0.89 89 0.91 91 86.6–95.4
CKD: Chronic kidney disease, ERP: Estimated resident population, 18+: aged 18 years and older.
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Supplementary table 3: Prevalence of chronic kidney disease in Tasmania by geographical region
Hobart and South East Launceston and North East West and North West
Crude Age standardised Crude Age standardised Crude Age standardised
No. No. No.
Year ERP with per % per 95% ERP with per % per 95% ERP with per % per 95%
(18+)* CKD 10,000 10,000 CI (18+)* CKD 10,000 10,000 CI (18+)* CKD 10,000 10,000 CI
2004 179769 2976 166 1.61 161 155.2–166.8 104030 1058 102 1 100 94–106 81798 1466 179 1.7 170 161.3–178.7
2005 181955 6015 331 3.18 318 310–326 105087 2263 215 2.08 208 199.4–216.6 82228 3041 370 3.43 343 330.8–355.2
2006 183977 7840 426 4.04 404 395.1–412.9 105711 3371 319 3.06 306 295.7–316.3 83019 4111 495 4.49 449 435.3–462.7
2007 185872 8926 480 4.47 447 437.7–456.3 106748 4458 418 3.96 396 384.4–407.6 83892 4747 566 5.04 504 489.7–518.3
2008 188645 9640 511 4.73 473 463.6–482.4 107676 5083 472 4.39 439 426.9–451.1 84995 5056 595 5.23 523 508.6–537.4
2009 191739 10310 538 4.94 494 484.5–503.5 108816 5504 506 4.65 465 452.7–477.3 86184 5236 608 5.29 529 514.7–543.3
2010 194779 11058 568 5.17 517 507.4–526.6 109945 6012 547 4.96 496 483.5–508.5 86942 5515 634 5.45 545 530.6–559.4
2011 197022 11984 608 5.48 548 538.2–557.8 110876 6679 602 5.35 535 522.2–547.8 87330 5954 682 5.74 574 559.4–588.6
2012 198461 13326 671 5.93 593 582.9–603.1 110972 7260 654 5.71 571 557.9–584.1 87160 6491 745 6.13 613 598.1–627.9
2013 199837 14628 732 6.35 635 624.7–645.3 111043 7881 710 6.06 606 592.6–619.4 86926 7000 805 6.51 651 635.7–666.3
2014 201828 15139 750 6.37 637 626.9–647.1 111300 8414 756 6.33 633 619.5–646.5 86858 7388 851 6.73 673 657.7–688.3
2015 203988 15450 757 6.31 631 621.1–640.9 111707 8753 784 6.44 644 630.5–657.5 86816 7751 893 6.94 694 678.5–709.5
2016 206221 15667 760 6.22 622 612.3–631.7 112177 8972 800 6.49 649 635.6–662.4 86768 8149 939 7.13 713 697.5–728.5
2017 209302 16047 767 6.16 616 606.5–625.5 113231 9319 823 6.51 651 637.8–664.2 87195 8490 974 7.24 724 708.6–739.4
CKD: Chronic kidney disease, ERP: Estimated resident population, 18+: aged 18 years and older.
Supplementary table 4: CKD stages in each year
Stage determined by first eGFR of the year (or previous year(s))
Year Total Stage 3A Stage 3B Stage 4 Stage 5 Stage 5KRT
2004 5,470 2,364 (43.2%) 1,890 (34.6%) 771 (14.1%) 156 (2.9%) 289 (5.3%)
2005 10,871 5,403 (49.7%) 3,632 (33.4%) 1,309 (12.0%) 212 (2.0%) 315 (2.9%)
2006 13,932 7,290 (52.3%) 4,537 (32.6%) 1,545 (11.1%) 219 (1.6%) 341 (2.4%)
2007 15,866 8,617 (54.3%) 4,946 (31.2%) 1,736 (10.9%) 189 (1.2%) 378 (2.4%)
2008 16,202 9,095 (56.1%) 4,869 (30.1%) 1,646 (10.2%) 192 (1.2%) 400 (2.5%)
2009 16,671 9,327 (55.9%) 5,042 (30.2%) 1,689 (10.1%) 181 (1.1%) 432 (2.6%)
2010 18,168 10,276 (56.6%) 5,527 (30.4%) 1,728 (9.5%) 180 (1.0%) 457 (2.5%)
2011 20,406 11,648 (57.1%) 6,176 (30.3%) 1,908 (9.4%) 198 (1.0%) 476 (2.3%)
2012 22,330 12,998 (58.2%) 6,611 (29.6%) 1,996 (8.9%) 218 (1.0%) 507 (2.3%)
2013 24,541 14,419 (58.8%) 7,169 (29.2%) 2,187 (8.9%) 246 (1.0%) 520 (2.1%)
2014 24,295 14,440 (59.4%) 6,965 (28.7%) 2,136 (8.8%) 229 (0.9%) 525 (2.2%)
2015 24,167 14,505 (60.0%) 6,899 (28.5%) 1,998 (8.3%) 216 (0.9%) 549 (2.3%)
2016 24,657 14,805 (60.0%) 7,002 (28.4%) 2,067 (8.4%) 210 (0.9%) 573 (2.3%)
2017 25,513 15,381 (60.3%) 7,204 (28.2%) 2,122 (8.3%) 234 (0.9%) 572 (2.2%)
CKD: Chronic kidney disease, eGFR: estimated glomerular filtration rate, KRT: Kidney replacement therapy (dialysis or
transplantation).
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